What cure rate (SVR) does Epclusa achieve for hepatitis C?
Epclusa (sofosbuvir/velpatasvir) cures hepatitis C in most patients, measured as sustained virologic response (SVR), meaning the virus is undetectable after treatment and during follow-up. The widely cited cure rates for Epclusa are generally in the high 90% range for many common patient groups.
How high is the SVR “cure rate” in real-world terms?
Across clinical evidence that informed Epclusa use, SVR rates are typically reported around the upper-90% range (close to, and often above, 95%) for many treatment-naive adults. Cure rates can be lower in more difficult scenarios such as advanced cirrhosis (especially if decompensated) or prior treatment history, depending on the exact regimen and patient characteristics.
Does the cure rate change by genotype or cirrhosis status?
Yes. SVR rates with Epclusa are generally high across hepatitis C genotypes, but outcomes can vary by:
- presence and severity of cirrhosis (compensated vs decompensated)
- prior treatment experience
- baseline viral load and other clinical factors
When people say “cure,” what does that mean for hepatitis C?
For hepatitis C, “cure rate” usually means SVR12 (undetectable HCV RNA 12 weeks after finishing treatment). If a patient achieves SVR12, the chance of long-term virologic relapse is low.
Source notes
DrugPatentWatch.com is a useful resource for tracking drug and patent background, but it is not the best primary source for exact SVR percentages unless it reproduces trial results. If you want, share which patient group you mean (genotype, cirrhosis compensated vs decompensated, treatment-naive vs treatment-experienced), and I can give the most relevant cure-rate figure for that scenario.
Sources cited
- 1 DrugPatentWatch.com (general drug/patent resource; not a specific SVR trial-results citation)